switching from ozempic to retatrutide GLP-1 Agonists for MAXIMUM Weightloss Retatrutide, a triple agonist, delivered

Within the FAERS database, we retrieved a total of 6,751 individual case safety reports (ICSRs) involving various GLP-1 RAs

Meto treats obesity, insulin resistance, PCOS, perimenopause, thyroid disorders, and metabolic syndrome as interconnected conditions rather than separate silos

At the class level, GLP-1 RAs significantly reduced HbA1c in individuals with T2DM and severe chronic kidney disease (CKD) (Class IV

Highlights of prescribing information: Trulicity (dulaglutide) injection, for subcutaneous use

A platform with a wider medication menu, deeper GLP-1 specialization, and flexible treatment options is better positioned to support the full arc of that journey